Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

Dow Jones

03-24

1019 GMT - Novo Nordisk's diabetes treatment Ozempic faces falling sales amid U.S. share loss and price declines, Intron Health analysts write. "New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of [group] 2025 guidance on sales and EBIT." Intron Helath is 40% below 2030 consensus Ozempic sales, which could translate to a 16% cut to 2030 consensus group EBIT. The analysts suggest a profit warning is possible at or before first quarter results on May 7. However, results from a trial testing semaglutide as a treatment for Alzheimer's due this year "could be game changing." Intron Helath downgrades Novo to sell from buy and lowers its target price to 460 Danish kroner from 880 kroner. Shares fall 2.6% to 515.00 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

March 24, 2025 06:19 ET (10:19 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2521717557"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521717557\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2521717557?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-24 18:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521717557","market":"hk","top_or_hot":-1,"title":"Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1019 GMT - Novo Nordisk's diabetes treatment Ozempic faces falling sales amid U.S. share loss and price declines, Intron Health analysts write. \"New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of [group] 2025 guidance on sales and EBIT.\" Intron Helath is 40% below 2030 consensus Ozempic sales, which could translate to a 16% cut to 2030 consensus group EBIT. The analysts suggest a profit warning is possible at or before first quarter results on May 7. However, results from a trial testing semaglutide as a treatment for Alzheimer's due this year \"could be game changing.\" Intron Helath downgrades Novo to sell from buy and lowers its target price to 460 Danish kroner from 880 kroner. Shares fall 2.6% to 515.00 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 06:19 ET (10:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-24 18:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1019 GMT - Novo Nordisk's diabetes treatment Ozempic faces falling sales amid U.S. share loss and price declines, Intron Health analysts write. \"New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of [group] 2025 guidance on sales and EBIT.\" Intron Helath is 40% below 2030 consensus Ozempic sales, which could translate to a 16% cut to 2030 consensus group EBIT. The analysts suggest a profit warning is possible at or before first quarter results on May 7. However, results from a trial testing semaglutide as a treatment for Alzheimer's due this year \"could be game changing.\" Intron Helath downgrades Novo to sell from buy and lowers its target price to 460 Danish kroner from 880 kroner. Shares fall 2.6% to 515.00 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 06:19 ET (10:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2521717557","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521717557","pubTimestamp":1742811540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1019 GMT - Novo Nordisk's diabetes treatment Ozempic faces falling sales amid U.S. share loss and price declines, Intron Health analysts write. \"New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of [group] 2025 guidance on sales and EBIT.\" Intron Helath is 40% below 2030 consensus Ozempic sales, which could translate to a 16% cut to 2030 consensus group EBIT. The analysts suggest a profit warning is possible at or before first quarter results on May 7. However, results from a trial testing semaglutide as a treatment for Alzheimer's due this year \"could be game changing.\" Intron Helath downgrades Novo to sell from buy and lowers its target price to 460 Danish kroner from 880 kroner. Shares fall 2.6% to 515.00 kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德的Ozempic药物面临销售额下降——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"1019 GMT - Novo Nordisk's diabetes treatment Ozempic faces falling sales amid U.S. share loss and price declines, Intron Health analysts write. \"New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of [group] 2025 guidance on sales and EBIT.\" Intron Helath is 40% below 2030 consensus Ozempic sales, which could translate to a 16% cut to 2030 consensus group EBIT. The analysts suggest a profit warning is possible at or before first quarter results on May 7. However, results from a trial testing semaglutide as a treatment for Alzheimer's due this year \"could be game changing.\" Intron Helath downgrades Novo to sell from buy and lowers its target price to 460 Danish kroner from 880 kroner. Shares fall 2.6% to 515.00 kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2025 06:19 ET (10:19 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}